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ABSTRACT
Objective: Patients with severe asthma require high-dose inhaled corticosteroids, with or
without add-on treatments, to maintain asthma control. Because symptom control remains
unsatisfactory in some patients despite these therapies, maintenance therapy with oral
corticosteroids (OCS) remains considered a treatment option by physicians. Besides phys-
ician-diagnosed exacerbations, many patients intermittently self-medicate with OCS during
episodes of worsening symptoms or as a prevention of such episodes. However, long-term
OCS use is associated with several comorbidities that may decrease health-related quality of
life, worsen prognosis, and should ideally require monitoring and management. In this
review, we discuss the adverse effects of OCS use, the OCS-sparing effect of biologics in
severe asthma, and the need for optimal referral pathways to ensure the best outcomes for
those at-risk asthma patients.
Data sources: PubMed.
Study selection: Studies with results on the OCS-sparing effect of biologics in adult severe
asthma were selected.
Results: Chronic and intermittent OCS use in asthma is associated with considerable
adverse effects in asthma. Omalizumab, mepolizumab, benralizumab, and dupilumab reduce
the need for OCS in severe asthma, while also reducing the exacerbation rate and improv-
ing several patient-related outcomes.
Conclusion: Targeted biologic therapies have revolutionized the treatment of uncontrolled
severe asthma by reducing or even eliminating the need for OCS and improving other
major outcomes. Novel agents are now rapidly increasing the therapeutic armamentarium,
but additional efforts are needed to optimize referral pathways in order to ensure sustain-
able access to these therapies.
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Severe asthma is defined in the European Respiratory
Society and American Thoracic Society (ERS/ATS)
guidelines as asthma which requires treatment with
high-dosage inhaled corticosteroids (ICS) plus a
second controller (and/or systemic corticosteroids) to
prevent it from becoming uncontrolled, or asthma
which remains uncontrolled despite this therapy
(Table 1) (1). The distinction between uncontrolled
asthma and severe asthma is important; not all uncon-
trolled asthma is severe asthma and vice versa.
Patients with severe asthma are estimated to com-
prise approximately 10% of the total asthma population
(2,3), with approximately 40% of severe asthma
remaining uncontrolled (2,4). While severe asthma is
present in a minority of asthma patients, its contribu-
tion to asthma morbidity and economic burden is con-
siderable, especially if it remains uncontrolled (5–7).
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Uncontrolled asthma leads to more days off work (8),
a limitation in daily activities, a decreased health-
related quality of life and more frequent emergency
department visits, and hospitalizations compared to
controlled asthma (9). In addition, patients with
uncontrolled asthma require more medication, includ-
ing rescue inhaler use and oral corticosteroids
(OCS) (9).
ICS and ICS-long-acting beta2 agonist (LABA)
combination remain the mainstay therapies for
asthma. If these therapies are not sufficient to achieve
asthma control, confounding factors, such as poor
treatment adherence, poor inhaler technique, comor-
bidities, and exposure to modifiable risk factors,
should first be ruled out before increasing therapy
dosage or resorting to add-on treatments (10). If these
confounding factors are not adequately addressed, the
asthma is referred to as difficult-to-control asthma.
Only when patients require high-dosage ICS-LABA
therapy despite addressing all confounding factors,
the asthma is referred to as (refractory) severe
asthma (11). Based on this definition, a study in the
Netherlands indicated that only 20.5% of patients with
difficult-to-control asthma met the definition of
refractory severe asthma, corresponding to 3.6% of
the Dutch asthma population (12). When including
patients who require treatment with a high-dosage
ICS-LABA to prevent their asthma from becoming
uncontrolled after ICS-LABA tapering, this becomes
4.5% (12).
For patients with uncontrolled severe asthma,
short-term or maintenance OCS add-on therapy is
still widely used. It has been estimated that for 30% of
adult patients with severe asthma, OCS therapy is
used in addition to ICS to maintain an acceptable
level of asthma control (1). In a patient sample from a
national United Kingdom registry, 42% of patients
with refractory severe asthma were prescribed main-
tenance OCS at baseline and 57% at a median follow-
up of 3.1 years (13). In the Netherlands, approximately
20% of the asthma patients are prescribed OCS escal-
ation therapy one or more times a year on top of ICS
therapy (14), and in Belgium, 24% of severe asth-
matics were treated with OCS on a daily basis (15).
Long-term use of OCS is associated with many
comorbidities, as detailed later in this review. While,
historically, there were no real alternatives, various
OCS-sparing therapies now allow reducing or stop-
ping maintenance OCS therapy. In particular, some
immunosuppressants and add-on biologic therapies
are effective in reducing OCS exposure (16).
In this article, we review the burden of OCS in
severe asthma, and we provide an overview of the
OCS-sparing effect of various biologic therapies that
are currently available. Finally, ensuring that OCS
exposure is minimized and that the right patient
receives the right treatment requires a timely con-
firmation of the diagnosis of uncontrolled severe
asthma and a thorough patient characterization,
which both depend on optimal referral pathways. In
the discussion, we provide an expert opinion on this
later topic.
Burden of oral corticosteroids in severe asthma
Frequent or regular exposure to OCS is a common
cause of adverse events in various groups of patients,
with some of the most frequently reported morbid-
ities being osteoporosis, dyspeptic disorders, sleep
disturbance, hypertension, diabetes, bone fractures,
and cataract (17–19). In addition, withdrawal from
maintenance OCS therapy following long-term use
may result in prolonged adrenal insufficiency that
requires appropriate substitution and preventive
measures (20,21). For patients with severe asthma,
the burden of OCS use is high, and OCS-related
adverse events affect the majority. In a British cross-
sectional study, 93% of patients with severe asthma
were found to have at least one condition linked to
systemic corticosteroid exposure (22). The most
Table 1. ERS/ATS definition of severe asthma for patients aged "6 years.
Asthma that requires treatment with guidelines-suggested medications for GINA steps 4–5 asthma (high-dose ICS and LABA or leukotriene modifier/
theophylline) for the previous year or systemic CS for "50% of the previous year to prevent it from becoming “uncontrolled!” or which remains
“uncontrolled!” despite this therapy.
!Uncontrolled severe asthma is defined as at least one of the following:
1) Poor symptom control: ACQ consistently >1.5, ACT <20 (or “not well controlled” by NAEPP/GINA guidelines)
2) Frequent severe exacerbations: two or more bursts of systemic CS (>3 days each) in the previous year
3) Serious exacerbations: at least one hospitalization, ICU stay or mechanical ventilation in the previous year
4) Airflow limitation: after appropriate bronchodilator withhold FEV1 <80% predicted (in the face of reduced FEV1/FVC defined as less than the lower
limit of normal)
Controlled asthma that worsens on tapering of these high doses of ICS or systemic CS (or additional biologics)
ERS/ATS, European Respiratory Society and American Thoracic Society; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long-acting
beta antagonists; ACQ, asthma control questionnaire; ACT, asthma control test; NAEPP, National Asthma Education and Prevention Program; CS, cortico-
steroids; ICU, intensive care unit; FEV, forced expiratory volume. FVC, forced vital capacity.
Source: based on Chung et al. 2014 (1).
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important types of OCS-related morbidity are illus-
trated in Figure 1.
It is difficult to distinguish the corticosteroid bur-
den that is due to ICS therapy (especially with high
dosages), acute OCS use, and/or maintenance OCS in
patients with severe asthma. Also, the burden of top-
ical corticosteroids and OCS bursts for concomitant
sinonasal disease may add to the overall burden.
Moreover, randomized controlled trials (RCTs) that
generally run over a limited period are not designed
to study long-term adverse effects of OCS use.
Findings from a retrospective cohort study in the
United States suggest that each prescription for an
OCS results in a cumulative burden on current and
future health, regardless of dosage and duration. The
incidence of adverse events appears to increase with
each year of exposure, particularly for patients with
four or more prescriptions of OCS per year (even in
case of short-term bursts of OCS use), and results in
a greater risk of an adverse effect during the current
year (odds ratio [OR] range: 1.21–1.44 depending on
the adverse effect) (23). These data strongly argue
that even repeated short courses of OCS might con-
siderably impact patients’ health-related quality of
life. A recent systematic review of systemic cortico-
steroid use for asthma management further estab-
lishes that OCS use is prevalent in asthma
management and that risks of acute and chronic
complications increase with cumulative OCS dos-
age (24).
Methods
Data sources: PubMed. Methodology: An initial
search was performed in Aug 2018, with a final
update in Oct 2019, with the following search string:
((((“oral corticosteroid”[Title/Abstract] OR “systemic
corticosteroid”[Title/Abstract]) OR “oral glucocorticoid”
[Title/Abstract]) OR “systemic glucocorticoid”[Title/
Abstract]) AND (“antibody name”[MeSH Terms] OR
“antibody name”[All Fields])) AND (“2008/01/
01”[PDAT]: “3000”[PDAT]). Only original studies were
selected (i.e., comments, reviews, and meta-analysis, …
were excluded). Only studies with results on the OCS-
sparing effect of the biologics were selected. Studies in
children were excluded. Only articles in English were
included. Quality assessment (including use and details
of appropriate methods, baseline comparability of
groups, reporting of relevant outcomes, … ) was per-
formed by the authors and disagreements were resolved
through consensus. Out of 109 identified articles, 29
original studies met the criteria for inclusion. This art-
icle is written as a narrative review.
Results
OCS-sparing effect of biologic therapies
Several biologic therapies for the treatment of
uncontrolled severe asthma are currently available.
Omalizumab targets immunoglobulin E (IgE) and ben-
efits patients with allergic asthma. Other biologics tar-
get interleukin (IL)-5 (mepolizumab, reslizumab), IL-5
Figure 1. Burden of OCS in severe asthma.
OR, odds ratio; OCS, oral corticosteroids; GI, gastrointestinal.
Severe vs mild/moderate asthma data: Sweeney et al. (22); data for "4 OCS prescriptions: Sullivan et al. (23).
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receptor alpha (IL-5Ra) (benralizumab), and IL-4
receptor alpha (IL-4Ra) (dupilumab). The OCS-sparing
effect of these therapies, except for reslizumab, has
been shown in RCTs (Table 2). This is not surprising
considering that OCS are acting mainly on type 2
inflammation, and the current biologic therapies target
specific mediators of this pathway (i.e., IgE, IL-5, IL-4,
IL-13).
The OCS-sparing effect of omalizumab has been
evaluated in two RCTs of which the results were
heterogenous. In the double-blind, placebo-controlled
011 trial, there was no treatment benefit with omali-
zumab (52), possibly due to a poorly optimized OCS
dosage at baseline. In the randomized, open-label
EXALT study, patients on omalizumab reduced or
stopped OCS around twice as often as those on opti-
mized asthma therapy alone (25). In the double-blind,
placebo-controlled SIRIUS trial, mepolizumab resulted
in a median OCS dosage reduction of 50% versus pla-
cebo (OR: 2.39), 6% more patients able to discontinue
OCS versus placebo (OR: 1.67), and 36% of patients
not able to reduce OCS dosage (47). Benralizumab
every 8weeks resulted in a median OCS dosage reduc-
tion of 50% versus placebo (OR: 4.12), 33% more eli-
gible patients able to discontinue OCS versus placebo
(OR: 4.19), and 21% of patients not able to reduce
OCS dosage in the double-blind, placebo-controlled
ZONDA trial (50). The OCS-sparing effect of both
mepolizumab and benralizumab was maintained in
extension trials (53,54). Finally, dupilumab resulted in
a median OCS dosage reduction of 50% versus pla-
cebo, 23% more patients able to discontinue OCS ver-
sus placebo (OR: 2.74), and 14% of patients not able
to reduce OCS dosage in the double-blind, placebo-
controlled VENTURE trial (51).
Real-world observational studies confirm the OCS-
sparing effects of biologics in severe asthma. This is
the case for omalizumab, which has been available the
longest, but now also for mepolizumab and benralizu-
mab (Table 2). As the outcomes of both RCTs and
observational studies can be greatly impacted by the
study design (e.g., baseline characteristics of included
patients, OCS dosage at baseline), direct comparisons
between biologics cannot be made.
Discussion
Optimization of the patient journey before
initiation of a biologic – expert opinion
Currently, severe asthma patients often do not rou-
tinely receive the optimal care in a timely manner,
leading to possibly preventable OCS use and its
associated risks. To address this, an important chal-
lenge lies in the optimization of referral pathways, as
patients are sometimes confined in primary care or
are consulting several physicians before a clear care
pathway could be proposed.
First, it is important to create awareness at the gen-
eral practitioner (GP) level around timely referral of
patients who could have severe asthma. A niche con-
sists of at-risk patients who frequently take courses of
OCS or use OCS as a regular therapy could potentially
benefit from treatment with a biologic. Initiatives
around referral are best developed at a local level,
since clinical practice and organization of health care
can vary between different countries and regions. In
Belgium, the authors of this review agreed on a refer-
ral signal to identify patients who should be assessed
for referral to a pulmonologist to confirm the diagno-
sis and optimize therapy, including possible initiation
of a biologic therapy. Patients should be considered
for referral when they meet the following criteria: the
use of medium- to high-dosage ICS-LABA with at
least one OCS prescription for a respiratory indica-
tion. Referral to a list of ICS dose equivalences may
be useful (Table 3). Additionally, while repeated anti-
biotic use is not in itself indicative of severe asthma,
the use of medium- to high-dosage ICS-LABA with
two or more antibiotics prescriptions for a respiratory
indication should also be considered as a potential
referral signal. Antibiotics tend to be overused in the
acute setting by GPs as add-on to OCS or to avoid
OCS use (56). These criteria may be adapted based on
local experience to accommodate differences in prac-
tice. Alternatively, a more general referral signal to a
pulmonologist could be used, such as the use of OCS
for more than two weeks cumulative per year for a
respiratory indication.
To optimize referral and interplay between GPs
and pulmonologists specialized in the management of
Table 3. Low, medium, and high daily doses of inhaled
corticosteroids (mcg).
Adults and adolescents
Inhaled corticosteroid Low Medium High
Beclometasone dipropionate (CFC) 200–500 >500–1000 >1000
Beclometasone dipropionate (HFA) 100–200 >200–400 >400
Budesonide (DPI) 200–400 >400–800 >800
Ciclesonide (HFA) 80–160 >160–320 >320
Fluticasone furoate (DPI) 100 NA 200
Fluticasone propionate (DPI) 100–250 >250–500 >500
Fluticasone propionate (HFA) 100–250 >250–500 >500
Mometasone furoate 110–220 >220–440 >440
Triamcinolone acetonide 400–1000 >1000–2000 >2000
mcg, microgram; CFC, chlorofluorocarbon propellant; DPI, dry powder
inhaler; HFA, hydrofluoroalkane propellant.
Source: GINA – 2018 Pocket Guide for Asthma Management and
Prevention (55).
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severe asthma, better collaboration and communica-
tion could be put in place. For example, communica-
tion should be standardized in a way that meets the
GP’s requirements and biologics could be prescribed
by the pulmonologist and injected by the GP.
Pharmacists can also play a role in identifying
those patients that should be seen by a pulmonolo-
gist. This could be the case for asthma patients who
repeatedly receive OCS prescriptions for a respiratory
indication or have excessive use of short-acting beta
agonists. In Belgium, pharmacists are recommended
to have counseling interviews with asthma patients:
one information interview and one follow-up discussion
(“Begeleidingsgesprek Goed Gebruik Geneesmiddelen”
https://upb-avb.be/nl/dossiers/begeleidingsgesprekken-
nieuwe-medicatie-bnm/). Another possibility could be
the integration of pharmacy data with hospital patient
files, as is currently already the case in several coun-
tries. In countries where prescription data are central-
ized, a feedback system allowing GPs to be aware of
the total amount of OCS delivered to their patients
could be useful and at least prompt discussions about
current therapy.
Repeated measurements of blood eosinophils, as
well as total and specific serum IgE, should be stand-
ard along the patient journey because of their import-
ance for asthma characterization and choosing
between biologic therapies. When possible, blood sam-
ples should be taken before the administration of sys-
temic corticosteroids because these drastically and
rapidly decrease circulating eosinophils. When an
increased count of circulating eosinophils is observed
in an uncontrolled asthma patient by the GP or at the
emergency department, this should be flagged because
a count greater than 300 eosinophils per mL blood
strongly supports a diagnosis of eosinophilic asthma
(57,58). Of note, 300 eosinophils per mL blood lies
within the “normal” range (in a healthy population,
90% has an eosinophil level between 0.5 and 400 per
mL blood (59)). In addition, investigations are under-
way to establish new biomarkers or sets of biomarkers
that could be more reliable (60).
In several countries including Belgium, the reim-
bursement criteria for anti-IL-5 and anti-IL-5Ra
therapies currently include "300/mL blood eosinophils
during the last year and at initiation. This might be
problematic for patients on maintenance OCS, or for
patients with repeated serious asthma attacks who are
given systemic corticosteroids, as both settings lead to
depletion of blood eosinophils. Consequently, some
pulmonologists ask for an exception for reimburse-
ment. Others will try to temporarily lower the
patient’s OCS dosage allowing their eosinophil levels
to recover, although this entails a risk of worsening
asthma or exacerbations. Finally, some pulmonologists
may not even initiate a biologic at all. Hence, there is
an argument to be made to lower the eosinophil
threshold for reimbursement for patients on mainten-
ance OCS until a better biomarker becomes available.
When a patient is hospitalized or admitted to the
emergency department for an asthma attack, a pulmo-
nologist should be consulted, and a diagnosis of severe
asthma should be considered. In the absence of clin-
ical evidence for the efficacy of targeted biologic ther-
apy in the acute setting, systemic administration of
corticosteroids remains the standard of care. Of note,
early-phase studies exploring the use of biologics in
the acute setting have been performed and warrant
further investigation (61).
Patients with uncontrolled severe asthma are often
eligible for multiple biologic therapies. In the IDEAL
study, about one-third of patients eligible for mepoli-
zumab were also eligible for omalizumab. Of those
patients eligible for omalizumab, eligibility for mepoli-
zumab varied considerably depending on the eligibility
criteria used, ranging from 35% to 73% (62).
Responses to omalizumab and mepolizumab in com-
bined allergic and eosinophilic severe asthma will be
compared in the PREDICTUMAB study (63). The
importance of selecting the right biologic therapy for
the right patient is further exemplified by recent cost-
effectiveness analyses, advocating adjusting pricing
structures and directing biologic therapy to responders
(64,65). An updated algorithmic approach to identify-
ing patients who can be considered candidates for
biologics has recently been published by the Global
Initiative for Asthma. When choosing between bio-
logic therapies, local reimbursement criteria, predic-
tors of asthma response, cost, dosing frequency,
delivery route and patient preference should be con-
sidered (https://ginasthma.org/severeasthma/)
Conclusion
OCS have long been the only option for uncontrolled
severe asthma patients, especially for patients non-
allergic severe asthma. However, OCS use has a great
patient and societal burden, especially in case of long-
term use. Therefore, OCS should no longer be consid-
ered as a first-line add-on treatment in the long term,
and repeated intermittent OCS use should be avoided
since novel biologics offer a safer alternative that tar-
gets the same biological processes. OCS should be
tapered to a minimal dosage at which asthma control
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is maintained. To ensure that OCS exposure is mini-
mized and that the right patient receives the right sus-
tainable therapy, it is critical to optimize the patient’s
journey, to determine the asthma endotype of patients
via existing biomarkers (serum IgE, blood and/or spu-
tum eosinophils, exhaled NO) and to develop new
biomarkers and predictors of (non)response to bio-
logic therapies. Finally, it is of utmost importance to
correctly diagnose severe asthma before resorting to
any add-on therapy. Patients whose asthma remains
difficult to control with ICS should first be assessed
for therapy adherence, correct use of inhaler devices,
comorbidities, and exposure to modifiable risk factors.
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